APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cholera Vaccine (Oral Route)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cholera Vaccine (Oral Route) Market Outlook and Growth Opportunities 2026

26 December 2025198 pages

Choose your research edition.

Industry ResearchCholera Vaccine (Oral Route) Industry Research Report 2026109 pages · $2,950 USDIndustry Growth & TrendsGlobal Cholera Vaccine (Oral Route) Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Cholera Vaccine (Oral Route) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cholera Vaccine (Oral Route) Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Cholera Vaccine (Oral Route) Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Cholera Vaccine (Oral Route) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cholera Vaccine (Oral Route) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cholera Vaccine (Oral Route) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cholera Vaccine (Oral Route) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cholera Vaccine (Oral Route) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cholera Vaccine (Oral Route) market include EuBiologics, PaxVax, Valneva and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cholera Vaccine (Oral Route) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cholera Vaccine (Oral Route) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cholera Vaccine (Oral Route) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cholera Vaccine (Oral Route) market size, projected growth trends, production technologies, key applications, and end-use industries.

Cholera Vaccine (Oral Route) Segment by Company

EuBiologics

PaxVax

Valneva

Sanofi

Cholera Vaccine (Oral Route) Segment by Type

Dukoral

Shanchol

Vaxchora

Others

Cholera Vaccine (Oral Route) Segment by Application

Pharmaceutical & Biotechnology Companies

Hospital

Research & Academic Laboratories

Others

Cholera Vaccine (Oral Route) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cholera Vaccine (Oral Route) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Cholera Vaccine (Oral Route) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cholera Vaccine (Oral Route) significant trends, drivers, influence factors in global and regions.

6. To analyze Cholera Vaccine (Oral Route) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cholera Vaccine (Oral Route) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cholera Vaccine (Oral Route) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cholera Vaccine (Oral Route).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cholera Vaccine (Oral Route) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cholera Vaccine (Oral Route) industry.

Chapter 3: Detailed analysis of Cholera Vaccine (Oral Route) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Cholera Vaccine (Oral Route) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Cholera Vaccine (Oral Route) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cholera Vaccine (Oral Route) Industry Trends Table 2. Cholera Vaccine (Oral Route) Industry Drivers Table 3. Cholera Vaccine (Oral Route) Industry Opportunities and Challenges Table 4. Cholera Vaccine (Oral Route) Industry Restraints Table 5. Global Cholera Vaccine (Oral Route) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cholera Vaccine (Oral Route) Revenue Share by Company (2021-2026) Table 7. Global Cholera Vaccine (Oral Route) Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Cholera Vaccine (Oral Route) Sales Volume Share by Company (2021-2026) Table 9. Global Cholera Vaccine (Oral Route) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Cholera Vaccine (Oral Route) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Cholera Vaccine (Oral Route) Key Company Manufacturing Base & Headquarters Table 12. Global Cholera Vaccine (Oral Route) Company, Product Type & Application Table 13. Global Cholera Vaccine (Oral Route) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Cholera Vaccine (Oral Route) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Dukoral Table 18. Significant Companies of Shanchol Table 19. Significant Companies of Vaxchora Table 20. Significant Companies of Others Table 21. Global Cholera Vaccine (Oral Route) Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Cholera Vaccine (Oral Route) Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Cholera Vaccine (Oral Route) Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Cholera Vaccine (Oral Route) Sales Volume Share by Type (2021-2026) Table 25. Global Cholera Vaccine (Oral Route) Sales Volume Share by Type (2027-2032) Table 26. Global Cholera Vaccine (Oral Route) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Cholera Vaccine (Oral Route) Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Cholera Vaccine (Oral Route) Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Cholera Vaccine (Oral Route) Sales Value Share by Type (2021-2026) Table 30. Global Cholera Vaccine (Oral Route) Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Pharmaceutical & Biotechnology Companies Table 32. Significant Companies of Hospital Table 33. Significant Companies of Research & Academic Laboratories Table 34. Significant Companies of Others Table 35. Global Cholera Vaccine (Oral Route) Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Cholera Vaccine (Oral Route) Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Cholera Vaccine (Oral Route) Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Cholera Vaccine (Oral Route) Sales Volume Share by Application (2021-2026) Table 39. Global Cholera Vaccine (Oral Route) Sales Volume Share by Application (2027-2032) Table 40. Global Cholera Vaccine (Oral Route) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Cholera Vaccine (Oral Route) Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Cholera Vaccine (Oral Route) Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Cholera Vaccine (Oral Route) Sales Value Share by Application (2021-2026) Table 44. Global Cholera Vaccine (Oral Route) Sales Value Share by Application (2027-2032) Table 45. Global Cholera Vaccine (Oral Route) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Cholera Vaccine (Oral Route) Sales by Region (2021-2026) & (K Units) Table 47. Global Cholera Vaccine (Oral Route) Sales Market Share by Region (2021-2026) Table 48. Global Cholera Vaccine (Oral Route) Sales by Region (2027-2032) & (K Units) Table 49. Global Cholera Vaccine (Oral Route) Sales Market Share by Region (2027-2032) Table 50. Global Cholera Vaccine (Oral Route) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Cholera Vaccine (Oral Route) Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Cholera Vaccine (Oral Route) Sales Value Share by Region (2021-2026) Table 53. Global Cholera Vaccine (Oral Route) Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Cholera Vaccine (Oral Route) Sales Value Share by Region (2027-2032) Table 55. Global Cholera Vaccine (Oral Route) Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Cholera Vaccine (Oral Route) Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Cholera Vaccine (Oral Route) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Cholera Vaccine (Oral Route) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Cholera Vaccine (Oral Route) Sales by Country (2021-2026) & (K Units) Table 60. Global Cholera Vaccine (Oral Route) Sales Market Share by Country (2021-2026) Table 61. Global Cholera Vaccine (Oral Route) Sales by Country (2027-2032) & (K Units) Table 62. Global Cholera Vaccine (Oral Route) Sales Market Share by Country (2027-2032) Table 63. Global Cholera Vaccine (Oral Route) Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Cholera Vaccine (Oral Route) Sales Value Market Share by Country (2021-2026) Table 65. Global Cholera Vaccine (Oral Route) Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Cholera Vaccine (Oral Route) Sales Value Market Share by Country (2027-2032) Table 67. EuBiologics Company Information Table 68. EuBiologics Business Overview Table 69. EuBiologics Cholera Vaccine (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. EuBiologics Cholera Vaccine (Oral Route) Product Portfolio Table 71. EuBiologics Recent Development Table 72. PaxVax Company Information Table 73. PaxVax Business Overview Table 74. PaxVax Cholera Vaccine (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. PaxVax Cholera Vaccine (Oral Route) Product Portfolio Table 76. PaxVax Recent Development Table 77. Valneva Company Information Table 78. Valneva Business Overview Table 79. Valneva Cholera Vaccine (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Valneva Cholera Vaccine (Oral Route) Product Portfolio Table 81. Valneva Recent Development Table 82. Sanofi Company Information Table 83. Sanofi Business Overview Table 84. Sanofi Cholera Vaccine (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Sanofi Cholera Vaccine (Oral Route) Product Portfolio Table 86. Sanofi Recent Development Table 87. Key Raw Materials Table 88. Raw Materials Key Suppliers Table 89. Cholera Vaccine (Oral Route) Distributors List Table 90. Cholera Vaccine (Oral Route) Customers List Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Cholera Vaccine (Oral Route) Product Image Figure 2. Global Cholera Vaccine (Oral Route) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cholera Vaccine (Oral Route) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Cholera Vaccine (Oral Route) Sales (2021-2032) & (K Units) Figure 5. Global Cholera Vaccine (Oral Route) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Cholera Vaccine (Oral Route) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Dukoral Image Figure 10. Shanchol Image Figure 11. Vaxchora Image Figure 12. Others Image Figure 13. Global Cholera Vaccine (Oral Route) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Cholera Vaccine (Oral Route) Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Cholera Vaccine (Oral Route) Sales Volume Share by Type (2021-2032) Figure 16. Global Cholera Vaccine (Oral Route) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Cholera Vaccine (Oral Route) Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Cholera Vaccine (Oral Route) Sales Value Share by Type (2021-2032) Figure 19. Pharmaceutical & Biotechnology Companies Image Figure 20. Hospital Image Figure 21. Research & Academic Laboratories Image Figure 22. Others Image Figure 23. Global Cholera Vaccine (Oral Route) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Cholera Vaccine (Oral Route) Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Cholera Vaccine (Oral Route) Sales Volume Share by Application (2021-2032) Figure 26. Global Cholera Vaccine (Oral Route) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Cholera Vaccine (Oral Route) Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Cholera Vaccine (Oral Route) Sales Value Share by Application (2021-2032) Figure 29. Global Cholera Vaccine (Oral Route) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Cholera Vaccine (Oral Route) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Cholera Vaccine (Oral Route) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Cholera Vaccine (Oral Route) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Cholera Vaccine (Oral Route) Sales Value (2021-2032) & (US$ Million) Figure 34. North America Cholera Vaccine (Oral Route) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Cholera Vaccine (Oral Route) Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Cholera Vaccine (Oral Route) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Cholera Vaccine (Oral Route) Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Cholera Vaccine (Oral Route) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Cholera Vaccine (Oral Route) Sales Value (2021-2032) & (US$ Million) Figure 40. South America Cholera Vaccine (Oral Route) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Cholera Vaccine (Oral Route) Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Cholera Vaccine (Oral Route) Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Cholera Vaccine (Oral Route) Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Cholera Vaccine (Oral Route) Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Dukoral
  • Shanchol
  • Vaxchora
  • Others
Applications
  • Pharmaceutical & Biotechnology Companies
  • Hospital
  • Research & Academic Laboratories
  • Others
Companies covered
  • EuBiologics
  • PaxVax
  • Valneva
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cholera Vaccine (Oral Route) Sales Value (2021-2032)
  4. 1.2.2 Global Cholera Vaccine (Oral Route) Sales Volume (2021-2032)
  5. 1.2.3 Global Cholera Vaccine (Oral Route) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Cholera Vaccine (Oral Route) Market Dynamics
  1. 2.1 Cholera Vaccine (Oral Route) Industry Trends
  2. 2.2 Cholera Vaccine (Oral Route) Industry Drivers
  3. 2.3 Cholera Vaccine (Oral Route) Industry Opportunities and Challenges
  4. 2.4 Cholera Vaccine (Oral Route) Industry Restraints
3 Cholera Vaccine (Oral Route) Market by Company
  1. 3.1 Global Cholera Vaccine (Oral Route) Company Revenue Ranking in 2025
  2. 3.2 Global Cholera Vaccine (Oral Route) Revenue by Company (2021-2026)
  3. 3.3 Global Cholera Vaccine (Oral Route) Sales Volume by Company (2021-2026)
  4. 3.4 Global Cholera Vaccine (Oral Route) Average Price by Company (2021-2026)
  5. 3.5 Global Cholera Vaccine (Oral Route) Company Ranking (2024-2026)
  6. 3.6 Global Cholera Vaccine (Oral Route) Company Manufacturing Base and Headquarters
  7. 3.7 Global Cholera Vaccine (Oral Route) Company Product Type and Application
  8. 3.8 Global Cholera Vaccine (Oral Route) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Cholera Vaccine (Oral Route) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Cholera Vaccine (Oral Route) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Cholera Vaccine (Oral Route) Market by Type
  1. 4.1 Cholera Vaccine (Oral Route) Type Introduction
  2. 4.1.1 Dukoral
  3. 4.1.2 Shanchol
  4. 4.1.3 Vaxchora
  5. 4.1.4 Others
  6. 4.2 Global Cholera Vaccine (Oral Route) Sales Volume by Type
  7. 4.2.1 Global Cholera Vaccine (Oral Route) Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Cholera Vaccine (Oral Route) Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Cholera Vaccine (Oral Route) Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Cholera Vaccine (Oral Route) Sales Value by Type
  11. 4.3.1 Global Cholera Vaccine (Oral Route) Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Cholera Vaccine (Oral Route) Sales Value by Type (2021-2032)
  13. 4.3.3 Global Cholera Vaccine (Oral Route) Sales Value Share by Type (2021-2032)
5 Cholera Vaccine (Oral Route) Market by Application
  1. 5.1 Cholera Vaccine (Oral Route) Application Introduction
  2. 5.1.1 Pharmaceutical & Biotechnology Companies
  3. 5.1.2 Hospital
  4. 5.1.3 Research & Academic Laboratories
  5. 5.1.4 Others
  6. 5.2 Global Cholera Vaccine (Oral Route) Sales Volume by Application
  7. 5.2.1 Global Cholera Vaccine (Oral Route) Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Cholera Vaccine (Oral Route) Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Cholera Vaccine (Oral Route) Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Cholera Vaccine (Oral Route) Sales Value by Application
  11. 5.3.1 Global Cholera Vaccine (Oral Route) Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Cholera Vaccine (Oral Route) Sales Value by Application (2021-2032)
  13. 5.3.3 Global Cholera Vaccine (Oral Route) Sales Value Share by Application (2021-2032)
6 Cholera Vaccine (Oral Route) Regional Sales and Value Analysis
  1. 6.1 Global Cholera Vaccine (Oral Route) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cholera Vaccine (Oral Route) Sales by Region (2021-2032)
  3. 6.2.1 Global Cholera Vaccine (Oral Route) Sales by Region: 2021-2026
  4. 6.2.2 Global Cholera Vaccine (Oral Route) Sales by Region (2027-2032)
  5. 6.3 Global Cholera Vaccine (Oral Route) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Cholera Vaccine (Oral Route) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Cholera Vaccine (Oral Route) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Cholera Vaccine (Oral Route) Sales Value by Region (2027-2032)
  9. 6.5 Global Cholera Vaccine (Oral Route) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Cholera Vaccine (Oral Route) Sales Value (2021-2032)
  12. 6.6.2 North America Cholera Vaccine (Oral Route) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Cholera Vaccine (Oral Route) Sales Value (2021-2032)
  15. 6.7.2 Europe Cholera Vaccine (Oral Route) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Cholera Vaccine (Oral Route) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Cholera Vaccine (Oral Route) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Cholera Vaccine (Oral Route) Sales Value (2021-2032)
  21. 6.9.2 South America Cholera Vaccine (Oral Route) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Cholera Vaccine (Oral Route) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Cholera Vaccine (Oral Route) Sales Value Share by Country, 2025 VS 2032
7 Cholera Vaccine (Oral Route) Country-level Sales and Value Analysis
  1. 7.1 Global Cholera Vaccine (Oral Route) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cholera Vaccine (Oral Route) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Cholera Vaccine (Oral Route) Sales by Country (2021-2032)
  4. 7.3.1 Global Cholera Vaccine (Oral Route) Sales by Country (2021-2026)
  5. 7.3.2 Global Cholera Vaccine (Oral Route) Sales by Country (2027-2032)
  6. 7.4 Global Cholera Vaccine (Oral Route) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Cholera Vaccine (Oral Route) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Cholera Vaccine (Oral Route) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Cholera Vaccine (Oral Route) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Cholera Vaccine (Oral Route) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Cholera Vaccine (Oral Route) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 EuBiologics
  2. 8.1.1 EuBiologics Company Information
  3. 8.1.2 EuBiologics Business Overview
  4. 8.1.3 EuBiologics Cholera Vaccine (Oral Route) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 EuBiologics Cholera Vaccine (Oral Route) Product Portfolio
  6. 8.1.5 EuBiologics Recent Developments
  7. 8.2 PaxVax
  8. 8.2.1 PaxVax Company Information
  9. 8.2.2 PaxVax Business Overview
  10. 8.2.3 PaxVax Cholera Vaccine (Oral Route) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 PaxVax Cholera Vaccine (Oral Route) Product Portfolio
  12. 8.2.5 PaxVax Recent Developments
  13. 8.3 Valneva
  14. 8.3.1 Valneva Company Information
  15. 8.3.2 Valneva Business Overview
  16. 8.3.3 Valneva Cholera Vaccine (Oral Route) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Valneva Cholera Vaccine (Oral Route) Product Portfolio
  18. 8.3.5 Valneva Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Cholera Vaccine (Oral Route) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Cholera Vaccine (Oral Route) Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cholera Vaccine (Oral Route) Value Chain Analysis
  2. 9.1.1 Cholera Vaccine (Oral Route) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cholera Vaccine (Oral Route) Sales Mode & Process
  6. 9.2 Cholera Vaccine (Oral Route) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cholera Vaccine (Oral Route) Distributors
  9. 9.2.3 Cholera Vaccine (Oral Route) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst